

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pathophysiology

ESPS manuscript NO: 12381

Title: Management of acute severe ulcerative colitis

Reviewer code: 00058269

Science editor: Fang-Fang Ji

Date sent for review: 2014-07-06 15:03

Date reviewed: 2014-07-06 16:12

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Existing	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

Interesting and relevant review, mostly for gastroenterologists and internal medicine physicians

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pathophysiology

ESPS manuscript NO: 12381

Title: Management of acute severe ulcerative colitis

Reviewer code: 00049305

Science editor: Fang-Fang Ji

Date sent for review: 2014-07-06 15:03

Date reviewed: 2014-07-08 14:29

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This review paper described the current approaches of clinical therapy of severe UC patients. Several points need to be addressed as follows: 1, In introduction part, authors only described the severe UC according to Truelove criteria. Please also describe other criteria such as Mayo classification 2, In Corticosteroids Part, please also show how to manage disease under special conditions, such as steroid-dependent and -resistant manners. 3, Please describe other potential biological therapy, in addition to infliximab. 4, In Surgery part, please also add other indications such as carcinoma, perianal abscess. please describe the procedure of surgery. 5, Please describe mucosal healing change in severe UC patients after medical therapy. 6, Does any herbal medicine play a role in the management of severe UC?

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pathophysiology

ESPS manuscript NO: 12381

Title: Management of acute severe ulcerative colitis

Reviewer code: 00030998

Science editor: Fang-Fang Ji

Date sent for review: 2014-07-06 15:03

Date reviewed: 2014-07-10 11:41

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Existing	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No records	<input checked="" type="checkbox"/> Major revision

COMMENTS TO AUTHORS

This review article describes the current status of management of severe ulcerative colitis. There are several issues which should be addressed. 1. Please make comments on the European Crohn's and Colitis Organisation (ECCO) guidelines. 2. There is sufficient data on Tacrolimus. 3. There is no data on other anti-TNF agents than infliximab. 4. Surgical procedure for acute UC should be presented. 5. The data on the risk of biologics and immunosuppressive agents on postoperative complications is insufficient. 5. Throughout the manuscript, previous meta-analyses or systematic review are rarely cited.

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pathophysiology

ESPS manuscript NO: 12381

Title: Management of acute severe ulcerative colitis

Reviewer code: 00073423

Science editor: Fang-Fang Ji

Date sent for review: 2014-07-06 15:03

Date reviewed: 2014-07-11 17:32

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Existing	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

In general, the review is clinically based and might be useful for practicing gastroenterologist. I have just some points to address: 1. The definition of ACUTE SEVERE ULCERATIVE COLITIS must be more clear? Which score is better, what parameters are of most importance? 2. The Cytomegalovirus detection by PCR could be stressed 3. The topical treatment in severe cases (especially enemas) is discussable? 4. The indication for blood transfusion 10mg/dl, must be based not only on the concentration of Hb.

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pathophysiology

ESPS manuscript NO: 12381

Title: Management of acute severe ulcerative colitis

Reviewer code: 02445675

Science editor: Fang-Fang Ji

Date sent for review: 2014-07-06 15:03

Date reviewed: 2014-07-14 01:04

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input checked="" type="checkbox"/> Rejection
<input checked="" type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Existing	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

This paper is a well written review of the current management of severe RCU. Although the authors well describe the correct approach to a patient affected by RCU and review all the modern treatments (i.e., medical and surgical), this article doesn't add anything to the current and common knowledge in IBD cure. For this reason, I do not advice to accept the paper for publication. Thank you for considering me as a Reviewer for this manuscript. Best regards.

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pathophysiology

ESPS manuscript NO: 12381

Title: Management of acute severe ulcerative colitis

Reviewer code: 00029041

Science editor: Fang-Fang Ji

Date sent for review: 2014-07-06 15:03

Date reviewed: 2014-07-14 08:02

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Existing	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

This review is well-written. Recent advances of adalimumab for ulcerative colitis should be described. References papers are listed below for example. Stidham RW, Lee TC, Higgins PD, Deshpande AR, Sussman DA, Singal AG, Elmunzer BJ, Saini SD, Vijan S, Waljee AK. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. *Aliment Pharmacol Ther.* 2014 Apr;39(7):660-71. Paul S, Moreau AC, Del Tedesco E, Rinaudo M, Phelip JM, Genin C, Peyrin-Biroulet L, Roblin X. Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. *Inflamm Bowel Dis.* 2014 Jul;20(7):1288-95.

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pathophysiology

ESPS manuscript NO: 12381

Title: Management of acute severe ulcerative colitis

Reviewer code: 00029041

Science editor: Fang-Fang Ji

Date sent for review: 2014-07-06 15:03

Date reviewed: 2014-07-14 08:03

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Existing	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

This review is well-written. Recent advances of adalimumab for ulcerative colitis should be described. References papers are listed below for example. Stidham RW, Lee TC, Higgins PD, Deshpande AR, Sussman DA, Singal AG, Elmunzer BJ, Saini SD, Vijan S, Waljee AK. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. *Aliment Pharmacol Ther.* 2014 Apr;39(7):660-71. Paul S, Moreau AC, Del Tedesco E, Rinaudo M, Phelip JM, Genin C, Peyrin-Biroulet L, Roblin X. Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. *Inflamm Bowel Dis.* 2014 Jul;20(7):1288-95.